C-TNMCMitotech
mitochondrial protection, oxidative stress, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-TNMC
C-TNMCC-TNMCmitochondrial protection, oxidative stress, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mitotech states that ageing follows a program that can be understood, shaped, and controlled, and that its business is focused on rapidly developing breakthrough pharmaceuticals based on the mitochondrially addressed antioxidant SkQ1. The company presents SkQ1 as having unique experimentally proven properties and as a promising drug candidate for treating several age-related disorders.
SourceMitotech presents ageing as a biological program that can be understood, shaped, and controlled, and says its business is built around rapidly developing breakthrough pharmaceuticals based on the mitochondrially addressed antioxidant SkQ1, which it describes as having unique experimentally proven properties and strong promise for treating several age-related disorders.
SourceMitotech states that ageing can be addressed through a disease-focused drug-development program and that mitochondria-targeted antioxidants have unique experimentally proven properties that make them promising candidates for treating many age-related disorders, including ophthalmic, neurodegenerative, cardiovascular, metabolic, and rare genetic conditions.
SourceMitotech presents aging as a biological program that can be understood, shaped, and controlled, and states that its business is focused on rapidly developing breakthrough pharmaceuticals based on the mitochondrially targeted antioxidant SkQ1. The company says SkQ1 has unique experimentally proven properties and is a promising drug candidate for several age-related disorders, with clinical development underway in Russia and the U.S.
Source